Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment

BACKGROUND: The currently recommended treatment algorithm for patients with advanced renal cell carcinoma who fail the first-line targeted therapy does not normally include pazopanib as a second-line treatment option. It would therefore be of interest to determine the efficiency of pazopanib in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Victor C., Kuo, Jung-Tsung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932732/
https://www.ncbi.nlm.nih.gov/pubmed/27377922
http://dx.doi.org/10.1186/s12894-016-0156-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932732/
https://www.ncbi.nlm.nih.gov/pubmed/27377922
http://dx.doi.org/10.1186/s12894-016-0156-4

Ejemplares similares